<?xml version='1.0' encoding='utf-8'?>
<document id="31729053"><sentence text="Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies."><entity charOffset="10-23" id="DDI-PubMed.31729053.s1.e0" text="Levetiracetam" /><entity charOffset="45-57" id="DDI-PubMed.31729053.s1.e1" text="Methotrexate" /><pair ddi="false" e1="DDI-PubMed.31729053.s1.e0" e2="DDI-PubMed.31729053.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31729053.s1.e0" e2="DDI-PubMed.31729053.s1.e1" /></sentence><sentence text="High-dose methotrexate (HDMTX) is a commonly used treatment for hematologic malignancies involving the central nervous system"><entity charOffset="10-22" id="DDI-PubMed.31729053.s2.e0" text="methotrexate" /><entity charOffset="24-29" id="DDI-PubMed.31729053.s2.e1" text="HDMTX" /><pair ddi="false" e1="DDI-PubMed.31729053.s2.e0" e2="DDI-PubMed.31729053.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31729053.s2.e0" e2="DDI-PubMed.31729053.s2.e1" /></sentence><sentence text=" Two case reports described possible delayed methotrexate clearance in patients receiving concurrent levetiracetam, while a retrospective cohort study did not find this association"><entity charOffset="45-57" id="DDI-PubMed.31729053.s3.e0" text="methotrexate" /><entity charOffset="101-114" id="DDI-PubMed.31729053.s3.e1" text="levetiracetam" /><pair ddi="false" e1="DDI-PubMed.31729053.s3.e0" e2="DDI-PubMed.31729053.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31729053.s3.e0" e2="DDI-PubMed.31729053.s3.e1" /></sentence><sentence text=" The objective of this single-center, retrospective case-control study of 121 patients who received their first cycle of HDMTX was to investigate the association between HDMTX clearance time and concomitant levetiracetam use"><entity charOffset="207-220" id="DDI-PubMed.31729053.s4.e0" text="levetiracetam" /><entity charOffset="121-133" id="DDI-PubMed.31729053.s4.e1" text="HDMTX" /><entity charOffset="170-182" id="DDI-PubMed.31729053.s4.e2" text="HDMTX" /><pair ddi="false" e1="DDI-PubMed.31729053.s4.e1" e2="DDI-PubMed.31729053.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31729053.s4.e1" e2="DDI-PubMed.31729053.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31729053.s4.e1" e2="DDI-PubMed.31729053.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31729053.s4.e2" e2="DDI-PubMed.31729053.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31729053.s4.e2" e2="DDI-PubMed.31729053.s4.e0" /></sentence><sentence text=" The most common diagnosis was primary central nervous system lymphoma (47" /><sentence text="9%)" /><sentence text=" The mean HDMTX dose was 4601 mg/m2 (standard deviation [SD], 2052"><entity charOffset="10-14" id="DDI-PubMed.31729053.s7.e0" text="HDMTX" /></sentence><sentence text="6 mg/m2 )" /><sentence text=" Concurrent levetiracetam was administered in 30 of 121 patients (24"><entity charOffset="12-25" id="DDI-PubMed.31729053.s9.e0" text="levetiracetam" /></sentence><sentence text="8%), with a mean total daily levetiracetam dose of 1434"><entity charOffset="29-42" id="DDI-PubMed.31729053.s10.e0" text="levetiracetam" /></sentence><sentence text="4 mg (SD, 622" /><sentence text="9 mg; range, 900-3000 mg)" /><sentence text=" Baseline characteristics were similar between patients who received concomitant levetiracetam and those who did not"><entity charOffset="81-94" id="DDI-PubMed.31729053.s13.e0" text="levetiracetam" /></sentence><sentence text=" The mean time to methotrexate clearance was 82"><entity charOffset="18-30" id="DDI-PubMed.31729053.s14.e0" text="methotrexate" /></sentence><sentence text="5 hours (SD, 51" /><sentence text="2; 95% confidence interval, 69" /><sentence text="4-95" /><sentence text="7) in the concomitant levetiracetam group and 72"><entity charOffset="22-35" id="DDI-PubMed.31729053.s18.e0" text="levetiracetam" /></sentence><sentence text="4 hours (SD, 31" /><sentence text="2; 95% confidence interval, 61" /><sentence text="7-83" /><sentence text="0) in the nonlevetiracetam group, which was not significantly different (P &gt; "><entity charOffset="10-26" id="DDI-PubMed.31729053.s22.e0" text="nonlevetiracetam" /></sentence><sentence text="05), even in the subgroup receiving methotrexate doses &gt;3500 mg/m2 "><entity charOffset="36-48" id="DDI-PubMed.31729053.s23.e0" text="methotrexate" /></sentence><sentence text=" Grade 3 or higher toxicity occurred in 33" /><sentence text="3% of the concomitant levetiracetam group and in 34"><entity charOffset="22-35" id="DDI-PubMed.31729053.s25.e0" text="levetiracetam" /></sentence><sentence text="1% of nonconcomitant levetiracetam patients"><entity charOffset="21-34" id="DDI-PubMed.31729053.s26.e0" text="levetiracetam" /></sentence><sentence text=" This study, which, to our knowledge, is the first examining levetiracetam effect on only the first dose of HDMTX, supports the larger retrospective study finding no significant effect of levetiracetam on HDMTX clearance time, and suggests that administering concomitant levetiracetam does not affect HDMTX toxicity"><entity charOffset="61-74" id="DDI-PubMed.31729053.s27.e0" text="levetiracetam" /><entity charOffset="188-201" id="DDI-PubMed.31729053.s27.e1" text="levetiracetam" /><entity charOffset="271-284" id="DDI-PubMed.31729053.s27.e2" text="levetiracetam" /><entity charOffset="108-120" id="DDI-PubMed.31729053.s27.e3" text="HDMTX" /><entity charOffset="205-217" id="DDI-PubMed.31729053.s27.e4" text="HDMTX" /><entity charOffset="301-313" id="DDI-PubMed.31729053.s27.e5" text="HDMTX" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e0" e2="DDI-PubMed.31729053.s27.e0" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e0" e2="DDI-PubMed.31729053.s27.e3" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e0" e2="DDI-PubMed.31729053.s27.e1" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e0" e2="DDI-PubMed.31729053.s27.e4" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e0" e2="DDI-PubMed.31729053.s27.e2" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e0" e2="DDI-PubMed.31729053.s27.e5" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e3" e2="DDI-PubMed.31729053.s27.e3" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e3" e2="DDI-PubMed.31729053.s27.e1" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e3" e2="DDI-PubMed.31729053.s27.e4" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e3" e2="DDI-PubMed.31729053.s27.e2" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e3" e2="DDI-PubMed.31729053.s27.e5" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e1" e2="DDI-PubMed.31729053.s27.e1" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e1" e2="DDI-PubMed.31729053.s27.e4" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e1" e2="DDI-PubMed.31729053.s27.e2" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e1" e2="DDI-PubMed.31729053.s27.e5" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e4" e2="DDI-PubMed.31729053.s27.e4" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e4" e2="DDI-PubMed.31729053.s27.e2" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e4" e2="DDI-PubMed.31729053.s27.e5" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e2" e2="DDI-PubMed.31729053.s27.e2" /><pair ddi="false" e1="DDI-PubMed.31729053.s27.e2" e2="DDI-PubMed.31729053.s27.e5" /></sentence><sentence text="" /></document>